Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com
Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of... - June 07, 2024
Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies
Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024
Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions
Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions. Researchers can screen a protein of interest against 22 biologically relevant lipids in one assay in a single day at a lower price compared with existing commercial options. - October 04, 2023
Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics
Cayman and Navinci have partnered to bring next-generation proximity ligation-based solutions for spatial proteomics to US and Canada-based researchers. - July 13, 2023
New Traceable Opioid Material® Kit Expands Coverage to Other Emerging Drugs of Concern in Seized Samples and Toxicological Casework
Cayman Chemical and the Centers for Disease Control and Prevention (CDC) have released a new addition to the Traceable Opioid Material® Kits (TOM Kits®) product line that expands testing laboratory capabilities beyond synthetic opioids to include additional emerging drugs of abuse that are commonly found as co-drugs in fentanyl-containing samples. - April 30, 2023
CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods
The Cayman Biomedical Research Institute (CABRI) is offering research grants in amounts up to $100,000 to support essential research on specialized pro-resolving mediator (SPM) analytical methods. - August 26, 2022
Deadline Extended: CABRI Announces Undergraduate Fellowships and Scholarship Program
The Cayman Biomedical Research Institute (CABRI) is accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted from August 22 until September 18, 2022. - August 26, 2022
Cayman Chemical Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration
The National Institute of Dental and Craniofacial Research has awarded Cayman Chemical with a $1,700,500 grant to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage... - September 19, 2021
Cayman Develops Powerful, New Multiplex ELISA for Autoantibody Detection
Cayman Chemical's new Q-Plex™ Autoantibody Detection 10-Plex Panel, developed in collaboration with Quansys Biosciences, offers standardized, multiplex capabilities for the concurrent analysis of ten prominent analytes associated with rheumatoid arthritis or other autoimmune diseases. This... - May 16, 2021
Cayman Adds Nordic BioSite as Trusted Distributor
Cayman Chemical’s complete assay kit, protein, antibody, and biochemical portfolio is now more accessible to Denmark, Finland, Iceland, Norway, Sweden, and the Baltic countries as well as Russia through a distribution agreement with Nordic BioSite. Headquartered in Täby, Sweden, Nordic... - February 10, 2021
Cayman Breaks Ground on State-of-the-Art Facility Projecting Future Growth in R&D
Cayman held a groundbreaking ceremony to start the buildout of a $20 million research and development facility at its headquarters in Ann Arbor, MI. - November 07, 2020
Cayman Receives SBIR Grant for Alzheimer’s Research
The National Institute on Aging (NIA) has awarded Cayman Chemical with a Phase II Small Business Innovation Research (SBIR) grant to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies. - October 10, 2020
Grants Available for Undergraduate Students Seeking Research Experience
Cayman Biomedical Research Institute (CABRI) is now accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted until September 20, 2020, for awards to be distributed by November 2, 2020. Grants range from $2,000 - $5,000 and may be awarded as individual or group grants. - August 19, 2020
Cayman and GenScript Partner to Offer Neoantigen Profiling and Synthesis Expertise
Cayman and GenScript have come together to create a complete package of neoantigen discovery services. Through combined efforts, MHC-associated peptides are identified and verified as immunogenic to guide peptide synthesis for vaccine development. “Cayman provides a complete workflow enabling... - August 15, 2020
40 Women Researchers Receive $40,000 in Grants from Cayman and CABRI
Each year during Women’s History Month, Cayman provides travel grants to help women researchers attend conferences to benefit from and contribute to the larger scientific community. This year, because the COVID-19 pandemic caused most conferences to cancel or postpone and many academic labs to close, Cayman introduced a new program to help support women in research. A record high of forty women will benefit from Cayman’s Women in Research program this year. - July 01, 2020
Rare Diseases Research Funded by $220,000 in Grants from CABRI
In its ongoing commitment to funding research for new treatments for rare diseases, Cayman Biomedical Research Institute (CABRI) has announced its principle investigator and undergraduate awardees for the 2020 academic year. “We are excited to support these scientists actively researching... - March 12, 2020
Cayman Awarded 1.5 Million Dollar SBIR Grant
The NIH’s National Institute of Arthritis and Musculoskeletal & Skin Diseases (NIAMS) has awarded Cayman Chemical with a Phase II Small Business Innovation Research (SBIR) grant to develop its patented small molecule bone repair agent KMN-159. - September 25, 2019
Biosynthetic Technologies Inks Patent License Agreement with Cayman Chemical for the Global Pharmaceutical and R&D Markets
Biosynthetic Technologies (BT) today announced it has signed on with Cayman Chemical for the production and distribution of novel Estolide compounds for pharmaceutical testing applications. BT is excited to partner with Cayman Chemical to provide discovery and pre-clinical development services to... - September 05, 2019
Multiplex ELISAs Offer Powerful Profiling Capabilities
Cayman now offers multiplex immunoassay technology powered by Quansys Biosciences. This line of fully quantitative Q-Plex™ multiplex ELISAs and chemiluminescent Q-View™ imagers provides a highly sensitive means to simultaneously measure multiple markers using a single sample. - June 22, 2019
Matreya, LLC is Now a Part of Cayman Chemical Company to Better Serve the Lipid Community
Cayman Chemical, an industry-leading supplier of bioactive lipids, analytical standards, and contract lipidomic services, announced today that it has acquired Matreya, LLC, a lipid biochemical company located in State College, Pennsylvania, with strengths in synthesis, extraction, and purification of natural products. Matreya stocks a wide selection of high-purity sphingolipids, phospholipids, fatty acids and esters, and sterols to be used as research standards. - June 05, 2019
Cayman Partners with LIPID MAPS® to Support Continued Development of Key Lipidomic Research Resources
Cayman has increased its financial support of the LIPID MAPS® Lipidomics Gateway. The newly launched LIPID MAPS® website (June 2018) provides easy access to free tools and resources, including a searchable lipid structure database (with over 43,000 entries), mass spectrometry spectra prediction tools, lipid structure drawing tools, experimental protocols, systems biology pathway maps, statistical analysis tools, and a curated lipid standards database. - July 21, 2018
New Assay for Immunology Research Quantifies cGAS-Produced 2’3’-cGAMP in Cells
Sensitive and direct measurement of cGAMP levels in cell lysates is now possible with Cayman’s much-anticipated 2’3’-cGAMP ELISA Kit. Developed by Cayman scientists, in conjunction with expert nucleotide scientists at Biolog Life Science Institute in Germany, this competitive... - July 20, 2018
New Purpose-Built MaxSpec™ Standards Available for Quantitative Mass Spectrometry Analysis
Cayman Chemical has launched a new line of ready-to-use, quantitative lipid standards prepared specifically for mass spectrometry applications. This new line of MaxSpec™ analytical standards complements Cayman’s high-purity, basic research tools that researchers have been using for more... - April 18, 2018
Qualitative Identification of Synthetic Cannabinoids Using Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-QTOF/MS)
A presentation at the Southwestern Association of Toxicologists November 2017 scientific meeting in San Antonio, Texas highlighted the utility of Cayman’s Synthetic Cannabinoid Screening Library. This library is comprised of more than 350 synthetic cannabinoid standards, including parent... - December 14, 2017
Cayman Contributes Tandem Spectra Data to Cloud-Based Mass Spectral Library
Cayman Chemical is collaborating with ThermoFisher and HighChem to provide accurate and high quality tandem spectra to the mzCloud™ library of mass data. mzCloud™ is a web-based mass spectral database comprised of a curated collection of high- and low-resolution MSn spectra acquired... - September 16, 2017
All-In-One Smart Technology Solution for Cell Culture Imaging
Cayman Chemical is distributing the new InCellis® Smart Cell Imaging System from Bertin Technologies. The InCellis® is the first all-in-one cell imager developed to generate publication-quality images and time-lapse videos of cells on tissue slides or in cell culture. Multichannel... - July 26, 2017
ToxBox®: Plate-Based Tool for Cannabis Testing by LC-MS/MS
Cayman Chemical, in collaboration with PinPoint Testing, LLC and Biotage, has introduced the ToxBox® THC/THC Metabolite Pack, an all-inclusive tool to detect THC, the primary active constituent in Cannabis, and its main metabolites. ToxBox®, a proprietary brand of products by PinPoint... - June 23, 2017
Faster Quantitation Workflow with 10-Analyte Phytocannabinoid Mixture
Cayman has released Phytocannabinoid Mixture 10 (CRM), a quantitative, multi-analyte mixture for use as an analytical standard in the simultaneous detection of the ten most prevalent phytocannabinoids found in Cannabis plants. - June 14, 2017
New Microplate-Based Method to Measure OCR and ECA Under Steady-State [O2]
Cayman Chemical, in collaboration with BMG LABTECH GmbH, has developed a novel assay kit to measure mitochondrial function under a dynamic range of oxygen concentrations. The Mito Stress Test (ACU Format) is designed to measure oxygen consumption rate (OCR) and extracellular acidification (ECA)... - April 26, 2017
BreviTest Awarded Grant from National Institute on Drug Abuse to Optimize Device for Rapid Cannabis Testing
BreviTest Technologies has been awarded a $234,412 grant from the National Institute on Drug Abuse of the National Institutes of Health (NIH) to explore rapid testing for THC, the main active ingredient in cannabis. The federal funds, awarded under the NIH’s Small Business Innovation Research... - April 14, 2016
MD Anderson, Cayman Chemical, and Fannin Innovation Studio Form Therapeutics Company
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio have formed ACF Pharmaceuticals, LLC. The pre-clinical therapeutics company is dedicated to discovering and developing novel small molecule inhibitors for the treatment of a variety of... - September 17, 2015
Cayman Chemical and the University of Michigan Issued US Patent for SAM-Screener™ Epigenetic Methylation Test
The United States Patent and Trademark Office has issued a patent to Cayman Chemical and the University of Michigan claiming detection analyte probes based on a natural product mimic of the methyltransferase cofactor S-adenosylmethionine (SAM). Aptly named SAM-Screener™, these probes are the foundation of Cayman’s high-throughput, one-step florescent binding assays for identification of SAM-competitive methyltransferase inhibitors from small-molecule chemical libraries. - September 10, 2015